Table 3.
Peptides used in this study
| Peptides | Sequences |
|---|---|
| APN 28–43 | FITC-Ahx-ALSVVYAQEKNKNAEH |
| APN 52–70 | FITC-Ahx-TITTTAAITLDQSKPWNRY |
| APN 133–148 | FITC-Ahx-VLRGVGDSQVPEIDRT |
| APN 208–223 | FITC-Ahx-QSTDARKSFPCFDEPA |
| APN 226–244 | FITC-Ahx-ATFNITLIHPNNLTALSNM |
| APN 367–391 | FITC-Ahx-QSSSISNKERVVTVIAHELAHQWFG |
| APN 436–457 | FITC-Ahx-YRVMAVDALASSHPLTTPAEEV |
| APN 469–493 | FITC-Ahx-SISYSKGASVIRMLSNFLTEDLFKE |
| APN 553–568 | FITC-Ahx-KTGNISQKHFLLDSES |
| APN 580–598 | FITC-Ahx-WIVPISSIKNGVMQDHYWL |
| APN 652–670 | FITC-Ahx-VINRAQVIYDSFNLATAHM |
| APN 841–874 | FITC-Ahx-YLGYTLNPDLIRKQDATSTINSIASNVIGQPLAW |
| APN 901–916 | FITC-Ahx-GVTRRFSSEFELQQLE |
| F4ab 148–160 | FITC-Ahx-NASYAGVFGKGGV |
| F4ab 175–187 | FITC-Ahx-LRAIFYGGLTTTV |
| F4ab 199–217 | FITC-Ahx-AARTELFGSLSRNDILGQI |
| F4ac 149–161 | FITC-Ahx-NASYAGVLGRGGV |
| F4ac 176–188 | FITC-Ahx-LSSIFYGGLPRGS |
| F4ac 200–218 | FITC-Ahx-TKLFGSLSRNDILGQIQRV |
| F4ad 149–161 | FITC-Ahx-ASYAGALGRGGVT |
| F4ad 176–188 | FITC-Ahx-HAIFYGGLPTNVK |
| F4ad 200–218 | FITC-Ahx-ARTELFGSLSKNDILGQIQ |
| F4ab 148–160M | FITC-Ahx-NASYAGVFGKGAV |
| F4ac 200–218 M1 | FITC-Ahx-TALFGSLSRNDILGQIQRV |
| F4ac 200–218 M2 | FITC-Ahx-TKAFGSLSRNDILGQIQRV |
| F4ac 200–218 M3 | FITC-Ahx-TKLFASLSRNDILGQIQRV |
| F4ac 200–218 M4 | FITC-Ahx-TKLFGSASRNDILGQIQRV |
| F4ac 200–218 M5 | FITC-Ahx-TKLFGSLARNDILGQIQRV |
| F4ac 200–218 M6 | FITC-Ahx-TKLFGSLSRADILGQIQRV |
| F4ac 200–218 M7 | FITC-Ahx-TKLFGSLSRNDIAGQIQRV |
| F4ac 200–218 M8 | FITC-Ahx-TKLFGSLSRNDILAQIQRV |
| F4ac 200–218 M9 | FITC-Ahx-TKLFGSLSRNDILGQIQAV |
| F4ad 200–218M | FITC-Ahx-ERTELFGSLSKNDILGQIQ |
The point-mutant amino acid in FaeG peptides are marked in italic.